Search
Atopic Dermatitis Paid Clinical Trials in Nevada
A listing of 10 Atopic Dermatitis clinical trials in Nevada actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 10 of 10
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Atopic Dermatitis
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Nevada currently has 10 active clinical trials seeking participants for Atopic Dermatitis research studies. These trials are conducted in various cities, including Las Vegas, Henderson, Reno and Pahrump.
Featured Trial
Eczema Clinical Study
Recruiting
The purpose of this clinical study is to see whether an oral investigational medication can help to treat symptoms of moderate to severe Atopic Dermatitis (eczema).
Conditions:
Eczema
Atopic Dermatitis Eczema
Atopic Eczema
Eczema
Atopic
* Compensation for time may be available
Featured Trial
Eczema Clinical Trial for Children & Adolsecents
Recruiting
Enrolling candidates diagnosed with Atopic Dermatitis (Eczema). Compensation available.
Conditions:
Atopic Dermatitis
Eczema
Atopic Dermatitis Eczema
Dermatitis
Atopic
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).
Recruiting
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/22/2024
Locations: Site 10-118, Las Vegas, Nevada
Conditions: Atopic Dermatitis Eczema
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/17/2024
Locations: Jubilee Clinical Research Inc, Las Vegas, Nevada
Conditions: Atopic Dermatitis
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD
Recruiting
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
04/17/2024
Locations: Excel Clinical Research, Las Vegas, Nevada +2 locations
Conditions: Atopic Dermatitis
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
04/10/2024
Locations: Skin Cancer and Dermatology Institute, Reno, Nevada
Conditions: Atopic Dermatitis
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The coprimary objectives of the study are to:
evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™).
evaluate the efficacy of rocatinlimab, in combination with TCS/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/27/2024
Locations: Vivida Dermatology, Las Vegas, Nevada +1 locations
Conditions: Atopic Dermatitis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
03/27/2024
Locations: Jubilee Clinical Research Inc, Las Vegas, Nevada +3 locations
Conditions: Atopic Dermatitis
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis.
The estimated duration is 15-35 days for screening and then up to approximately day 378 (last dose on day 280 + 98 days safety follow-up) for all patients. Patients with a response at Week 16 (end of induction therapy) will be re-randomized for... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/11/2024
Locations: Jubilee Clinical Research, Las Vegas, Nevada +1 locations
Conditions: Moderate to Severe Atopic Dermatitis
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis
Recruiting
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.
OpSCF or placebo will be administered every 2 weeks for 14 weeks, and the efficacy will be assessed two weeks later. After that, subjects may choose to enter an Open Label Extension phase in which all subjects will receive OpSCF every 4 weeks for 40 additional weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/20/2024
Locations: Skin Cancer and Dermatology Institute, Reno, Nevada
Conditions: Atopic Dermatitis
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: ASLAN Investigative Site, Las Vegas, Nevada
Conditions: Atopic Dermatitis
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
Recruiting
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/04/2022
Locations: AkesoBio Investigative Site 2015, Las Vegas, Nevada
Conditions: Atopic Dermatitis
1 - 10 of 10